This is an international site for Sandostatin® LAR® and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Sandostatin LAR Information for US residents Sandostatin LAR Information for International Healthcare Professionals Sandostatin LAR Information for Patients Outside the US
Sandostatin® LAR® Delivers Powerful Efficacy and Unparalleled Evidence

Home > Resources > Glossary

Glossary

5-hydroxyindoleacetic acid (5-HIAA): a reliable, 24-hour urine test that is specific to carcinoid tumours. With this test, 5-HIAA is measured in the urine. 5-HIAA is a metabolite of serotonin, a natural chemical messenger that is overproduced in people with GEP NETs.

Acromegaly: a condition characterised by enlarged features; caused by overproduction of growth hormone and insulin-like growth factor-1.

Adenoma: a type of noncancerous tumour.

Amine: member of a group of chemical compounds formed from ammonia by replacement of 1 or more of the hydrogen atoms.

Carcinoid syndrome: the most common systemic clinical manifestation of carcinoid tumours; usually develops after a carcinoid tumour has metastasised, usually to the liver, and there is a substantial concentration of the hormones released by a tumour in the systemic circulation.

Chromogranin A (CgA) testing: a fast, easy blood test for testing all major types of GEP NETs.

Gastrin: a polypeptide hormone that is released from G cells, which are primarily located in the antrum region of the stomach.

Gastroenteropancreatic neuroendocrine tumours (GEP NETs): Neuroendocrine tumours of the gut and pancreas that may result in hypersecretion of a variety of hormones and other substances depending on the location of the tumour.

Growth hormone (GH): released by the pituitary gland and stimulates growth throughout the body.

Growth hormone-releasing hormone (GHRH): hypothalamic factor that stimulates the pituitary to release growth hormone.

Insulin-like growth factor-1 (IGF-1): a peptide that causes bone and tissue growth; is mostly produced in the liver when secretion of GH from the pituitary gland occurs; IGF-1 signals the pituitary to reduce GH production.

Neuroendocrine tumor (NET): the most common NET arises from neuroendocrine cells; primarily occurs in the appendix, ileum, rectum, and bronchus.

Octreoscan™ somatostatin receptor scintigraphy (SRS) testing: a highly accurate and versatile imaging test for all of the body's systems.

Octreotide: a synthetic analogue of somatostatin, used to treat certain conditions such as acromegaly and NETs.

Peptide: a member of a class of low-molecular-weight compounds that yields 2 or more amino acids on hydrolysis.

Serotonin: a monoamine vasocontrictor that has many physiologic properties in the body.

Somatostatin: a native hormone that inhibits several endocrine functions.